Remove 2020 Remove Packaging Remove Pharmaceutical Companies
article thumbnail

Rising Demand for Pharmaceutical Secondary Packaging Providers

Roots Analysis

This continuously growing pipeline of pharmaceutical drug products has inadvertently led to an increase in the demand for their associated primary packaging and Secondary Packaging solutions. . 3] Some of the advantages offered by pharmaceutical secondary packaging have been depicted below.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CMO Moves: Regulatory catalysts for drug manufacturing-April

Pharmaceutical Technology

Pharmaceutical companies regularly outsource different steps of drug manufacturing processes like parenteral manufacturing and packaging, solid dose, and small molecule or biologic active pharmaceutical ingredient (API) production, among others.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

article thumbnail

Halting Europe’s essential medicines manufacturing exodus

European Pharmaceutical Review

Between 2000 and 2020, Asian companies outperformed European companies for new approvals of CEPs, increasing their number CEPs from 183 to 2,369. This left pharmaceutical companies in Europe with no European API supply source, and only a few suppliers in Asia.

article thumbnail

Innovation across the healthcare system is needed to realise the value of medicines

pharmaphorum

From patients, patient bodies, pharmaceutical companies, and academia, to regulatory bodies, public institutions, and small and medium-sized enterprises (SMEs), all key stakeholders must come together to help the patients who most need new medicines to access them as quickly as possible. About the author.

article thumbnail

Ireland is open: The biologics boom boosting the Irish economy

pharmaphorum

With an attractive corporate tax rate and the youngest workforce in the EU, Ireland continues to be a popular destination for life science companies to settle. Although cities such as Dublin and Cork were the traditional centres for pharmaceutical companies, a new wave of regional investment is happening across the country.

Packaging 124